A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
Phase of Trial: Phase III
Latest Information Update: 14 Oct 2017
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Sponsors AbbVie
- 28 Jun 2017 Planned End Date changed from 5 Feb 2021 to 6 Jan 2021.
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 31 May 2017 Planned End Date changed from 1 Nov 2022 to 5 Feb 2021.